Brain-computer interface commercialization.

WHAT IT FOUND

This is a commercialization commentary about brain-computer interfaces, not a patient study.

It discusses Argus II's market failure and Onward Medical's phased strategy, with no clinical outcomes to change therapy.

What this paper is

This is a narrative commentary on commercialization of brain-computer interfaces. It discusses Argus II's market failure and Onward Medical's phased strategy, but reports no methods, no patient cohort and no clinical outcomes, so there is no finding to act on.

Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →